LPK-26, a novel κ-opioid receptor agonist with potent antinociceptive effects and low dependence potential

European Journal of Pharmacology

Volumn 584, Issue 2-3, 2008, Pages 306-311

  Tao, Yi Min ^a   Li, Qing Lin ^b   Zhang, Cong Fen ^b   Xu, Xue Jun ^a   Chen, Jie ^a   Ju, Ya Wen ^a   Chi, Zhi Qiang ^a   Long, Ya Qiu ^a   Liu, Jing Gen ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Opioid receptor; ( )U50,488H; Antinociception; LPK 26; Morphine; Physical dependence

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ACETIC ACID; BETA FUNALTREXAMINE; BINALTORPHIMINE; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; LPK 26; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTRINDOLE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; JUMPING; MALE; MONOTHERAPY; MORNING DOSAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; WRITHING TEST;

ACETIC ACID; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEAT; HUMANS; MALE; MICE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PROTEIN BINDING; PYRROLES; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; TIME FACTORS; TRANSFECTION;

EID: 41249091949     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.028     Document Type: Article

References (23)

1. Chen X.L., Lu G., Gong Y.X., Zhao L.C., Chen J., Chi Z.Q., Yang Y.M., Chen Z., Li Q.L., and Liu J.G. Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatment. Cell Res. 17 (2007) 689-700
2. Clark J.A., and Pasternak G.W. U50,488: a kappa-selective agent with poor affinity for mu1 opiate binding sites. Neuropharmacology 27 (1988) 331-332
3. Clark J.A., Liu L., Price M., Hersh B., Edelson M., and Pastemak G.W. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J. Pharmacol. Exp. Ther. 251 (1989) 461-468
4. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., Saitoh A., Suzuki T., Narita M., Tseng L., and Nagase H. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci. 65 (1999) 1685-1694
5. Fukagawa Y., Katz J.L., and Suzuki T. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats. Eur. J. Pharmacol. 170 (1989) 47-51
6. Hunter J.C., Leighton G.E., Meecham K.G., Boyle S.J., Horwell D.C., Rees D.C., and Hughes J. CI-977, a novel and selective agonist for the kappa-opioid receptor. Br. J. Pharmacol. 101 (1990) 183-189
7. Jiang Q., Heyman J.S., and Porreca F. Mu antagonist and kappa agonist properties of β-funaltrexamine (β-FNA): long lasting spinal antinociception. NIDA Res. Monogr. 95 (1989) 199-205
8. Kest B., Palmese C.A., Hopkins E., Adler M., Juni A., and Mogil S. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 115 (2002) 463-469
9. Lahti R.A., VonVoigtlander P.F., and Barsuhn C. Properties of a selective kappa agonist, U-50,488H. Life Sci. 31 (1982) 2257-2260
10. 3H]U-69593 a highly selective ligand for the opoid κ receptor. Eur. J. Pharmacol. 109 (1985) 281-284
11. Liu J.G., and Prather Paul L. Chronic exposure to μ-opioid agonists produces constitutive activation of μ-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol. Pharmacol. 60 (2001) 53-62
12. Mo Q.Y., Chen J., Zhu Y.C., Zhou D.H., Chi Z.Q., and Long Y.Q. 3-Pyrroline containing arylacetamides: a novel series of remarkably selective κ-agonists. Bioorg. Med. Chem. Lett. 12 (2002) 2287-2290
13. Pan Z.Z. mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol. Sci. 19 (1998) 94-98
14. Pasternak G.W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16 (1993) 1-18
15. Portoghese P.S., Lipkowski A.W., and Takemori A.E. Bimorphinans as highly selective potent kappa receptor antagonists. J. Med. Chem. 30 (1987) 238-239
16. Specker S., Wananukul W., Hat S., Ukami D., Nolin K., Hooke L., Kreek M.J., and Pentel P.R. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology 137 (1998) 326-332
17. Suzuki T., Narita M., Takahashi Y., Misawa M., and Nagase H. Effects of nor-binaltorphimine on the development of analgesic tolerance to and physical dependence on morphine. Eur. J. Pharmacol. 213 (1992) 91-97
18. Takemori A.E., Loh H.H., and Lee N.M. Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221 (1992) 223-226
19. Tsuji M., Takeda H., Matsumiya T., Negase H., Yamazaki M., Narita M., and Suzuki T. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci. 66 (2000) 353-358
20. Vanderah T.W., Schteingart C.D., Trojnar J., Junien J.L., Lai J., and Riviere P.J. FE200041 (d-Phe-d-Phe-d-Nle-d-Arg-NH2): a peripheral efficacious kappa opioid agonist with unprecedented selectivity. J. Pharmacol. Exp. Ther. 310 (2004) 326-333
21. Wang Y.L., Tang K., Inan S., Siebert D., Holzgrabe U., Lee D.Y.W., Huang P., Li J.G., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J. Pharmacol. Exp. Ther. 312 (2005) 220-230
22. 35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J. Pharmacol. Exp. Ther. 282 (1997) 676-684
23. Zukin R.S., Eghbali M., Olive D., Unterwald E.M., and Tempel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc. Natl. Acad. Sci. USA 85 (1988) 4061-4065